lidocaine has been researched along with Scleroderma, Systemic in 6 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " No systemic adverse event due to topical lidocaine were observed." | 5.46 | Lidocaine controls pain and allows safe wound bed preparation and debridement of digital ulcers in systemic sclerosis: a retrospective study. ( Bartoli, F; Braschi, F; Bruni, C; De Paulis, A; Fantauzzo, C; Fiori, G; Matucci-Cerinic, M; Paganelli, L; Rasero, L, 2017) |
| "Lidocaine seems to be an alternative treatment for scleroderma considering that: a) the patient's having excessive collagen deposits in tissues affected by scleroderma; b) the patient's demonstrating increased activity of the enzyme prolyl hydroxylase, an essential enzyme for the biosynthesis of collagen; and c) lidocaine's reducing the activity of prolyl hydroxylase." | 2.76 | Lidocaine for systemic sclerosis: a double-blind randomized clinical trial. ( Andrade, LE; Kayser, C; Riera, R; Souza, AW; Trevisani, VF; Yanagita, ET, 2011) |
| " No systemic adverse event due to topical lidocaine were observed." | 1.46 | Lidocaine controls pain and allows safe wound bed preparation and debridement of digital ulcers in systemic sclerosis: a retrospective study. ( Bartoli, F; Braschi, F; Bruni, C; De Paulis, A; Fantauzzo, C; Fiori, G; Matucci-Cerinic, M; Paganelli, L; Rasero, L, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braschi, F | 1 |
| Bartoli, F | 1 |
| Bruni, C | 1 |
| Fiori, G | 1 |
| Fantauzzo, C | 1 |
| Paganelli, L | 1 |
| De Paulis, A | 1 |
| Rasero, L | 1 |
| Matucci-Cerinic, M | 1 |
| Riera, R | 1 |
| Andrade, LE | 1 |
| Souza, AW | 1 |
| Kayser, C | 1 |
| Yanagita, ET | 1 |
| Trevisani, VF | 1 |
| Ozgocmen, S | 1 |
| Kaya, A | 1 |
| Coskun, BK | 1 |
| Roustit, M | 1 |
| Simmons, GH | 1 |
| Carpentier, P | 1 |
| Cracowski, JL | 1 |
| Lewis, GB | 1 |
| Eisele, JH | 1 |
| Reitan, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind Randomized Clinical Trial to Evaluate the Reduction of Pain in the Wounds Treatment Previously Applying Lidocaine Topical Solution vs Placebo, in the Outpatients Area.[NCT03676556] | Phase 3 | 46 participants (Anticipated) | Interventional | 2021-06-16 | Recruiting | ||
| Randomised, Double-blind Clinical Trial to Evaluate the Reduction of Pain in the Wounds Treatment Previously Applying Lidocaine Topical Solution vs Placebo[NCT02584335] | Phase 4 | 7 participants (Actual) | Interventional | 2015-07-31 | Terminated (stopped due to Difficulties with the recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for lidocaine and Scleroderma, Systemic
| Article | Year |
|---|---|
Lidocaine for systemic sclerosis: a double-blind randomized clinical trial.
Topics: Adult; Double-Blind Method; Female; Humans; Lidocaine; Male; Middle Aged; Scleroderma, Systemic; Tre | 2011 |
5 other studies available for lidocaine and Scleroderma, Systemic
| Article | Year |
|---|---|
Lidocaine controls pain and allows safe wound bed preparation and debridement of digital ulcers in systemic sclerosis: a retrospective study.
Topics: Aged; Anesthetics, Local; Debridement; Female; Fingers; Humans; Lidocaine; Male; Middle Aged; Pain; | 2017 |
Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma).
Topics: Administration, Oral; Administration, Topical; Anesthetics, Local; Anti-Infective Agents; Ciprofloxa | 2006 |
Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma).
Topics: Administration, Oral; Administration, Topical; Anesthetics, Local; Anti-Infective Agents; Ciprofloxa | 2006 |
Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma).
Topics: Administration, Oral; Administration, Topical; Anesthetics, Local; Anti-Infective Agents; Ciprofloxa | 2006 |
Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma).
Topics: Administration, Oral; Administration, Topical; Anesthetics, Local; Anti-Infective Agents; Ciprofloxa | 2006 |
Abnormal digital neurovascular response to local heating in systemic sclerosis.
Topics: Adolescent; Adult; Aged; Anesthetics, Local; Axons; Female; Fingers; Forearm; Hot Temperature; Human | 2008 |
Prolonged regional analgesia in scleroderma.
Topics: Amputation, Surgical; Analgesia; Bicarbonates; Dextrans; Female; Fingers; Humans; Hydrogen-Ion Conce | 1974 |
Scleroderma, Raynaud's phenomenon, and local anesthetics.
Topics: Aged; Anesthesia, Local; Humans; Lidocaine; Male; Raynaud Disease; Scleroderma, Systemic | 1971 |